Overview
Arthrogryposis multiplex congenita-whistling face syndrome, also known as Freeman-Sheldon syndrome (FSS) or distal arthrogryposis type 2A (DA2A) or craniocarpotarsal dystrophy, is a rare genetic disorder characterized by the combination of multiple joint contractures (arthrogryposis) and distinctive facial features. The hallmark facial appearance includes a very small, pursed mouth that resembles a whistling expression, prominent nasolabial folds, a small nose, deep-set eyes, and an H-shaped dimpling of the chin. The condition primarily affects the musculoskeletal system, with contractures most commonly involving the hands (clenched fists with ulnar deviation), feet (clubfoot or talipes equinovarus), and other joints. Patients may also experience restricted movement of the shoulders, elbows, hips, and knees. Additional features can include short stature, scoliosis or kyphosis, difficulty swallowing and feeding (particularly in infancy), speech difficulties due to the small oral opening (microstomia), and respiratory complications. Intelligence is typically normal, though developmental delays may occur secondary to physical limitations. Some patients experience malignant hyperthermia susceptibility during anesthesia, which is an important consideration for surgical planning. Treatment is multidisciplinary and primarily supportive. Surgical interventions may be needed to correct joint contractures, clubfoot, scoliosis, and to improve oral opening. Physical and occupational therapy are essential to maximize joint mobility and functional independence. Speech therapy may be beneficial for those with communication difficulties. Craniofacial surgery can address the restrictive facial features. Genetic counseling is recommended for affected families. The condition is caused by mutations in the MYH3 gene, which encodes embryonic myosin heavy chain, playing a critical role in fetal muscle development.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Arthrogryposis multiplex congenita-whistling face syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Arthrogryposis multiplex congenita-whistling face syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Arthrogryposis multiplex congenita-whistling face syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Arthrogryposis multiplex congenita-whistling face syndrome.
Community
No community posts yet. Be the first to share your experience with Arthrogryposis multiplex congenita-whistling face syndrome.
Start the conversation →Latest news about Arthrogryposis multiplex congenita-whistling face syndrome
No recent news articles for Arthrogryposis multiplex congenita-whistling face syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Arthrogryposis multiplex congenita-whistling face syndrome
What is Arthrogryposis multiplex congenita-whistling face syndrome?
Arthrogryposis multiplex congenita-whistling face syndrome, also known as Freeman-Sheldon syndrome (FSS) or distal arthrogryposis type 2A (DA2A) or craniocarpotarsal dystrophy, is a rare genetic disorder characterized by the combination of multiple joint contractures (arthrogryposis) and distinctive facial features. The hallmark facial appearance includes a very small, pursed mouth that resembles a whistling expression, prominent nasolabial folds, a small nose, deep-set eyes, and an H-shaped dimpling of the chin. The condition primarily affects the musculoskeletal system, with contractures mos
How is Arthrogryposis multiplex congenita-whistling face syndrome inherited?
Arthrogryposis multiplex congenita-whistling face syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Arthrogryposis multiplex congenita-whistling face syndrome typically begin?
Typical onset of Arthrogryposis multiplex congenita-whistling face syndrome is neonatal. Age of onset can vary across affected individuals.